Dostarlimab and niraparib in primary advanced ovarian cancer (original) (raw)

Additional Information:

This work was supported by GSK (no grant number).

Keywords:

Advanced ovarian cancer, dostarlimab, niraparib, first line, PD-(L)1inhibition, immunotherapy.

Authors:

Hardy-Bessard, A.-C., Pujade-Lauraine, E., Moore, R.G., Montestruc, F., Redondo, A., Mirza, M.R., Cibula, D., Ciuleanu, T.-E., Gilbert, L., Eitan, R., Zagouri, F., Pignata, S., Glasspool, R., Pfisterer, J., Phaëton, R., Anderson, C.K., Rodrigues, M., Gaba, L., Bakirtzi, E., Fauci, J.M., Kalbacher, E., Musa, F.B., Gorman, S., Duska, L.R., Gladieff, L., Braly, P., Joly, F., Thomes Pepin, J., Ray-Coquard, I., and Moore, K.N.

First Published:

First published in Annals of Oncology 36(12):1503-1513

Publisher Policy:

Reproduced under a Creative Commons licence